News and Announcements
Only 2 Days Left in the Shivom Presale!
- Published April 19, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Key Takeaways:
- Shivom’s OmiX Presale closes April 22nd, 12PM GMT
- Can’t contribute to the Presale- You can still earn up to 8% bonus on the purchase of first 15 000 ETH
Don’t miss your chance, contribute now!
This is a quick reminder that the OmiX Presale is ending soon! April 22nd, 2018 is the last day and the sale will close at 12PM GMT.
If you have not yet contributed to our presale there’s still time and rewards to be earned! You can still earn up to 8% bonus on the purchase of first 15 000 ETH. This bonus started at 10% on April 16th and will keep decreasing by 1% each day. It is also your last chance to buy OmiX tokens at 1 ETH = 7000 OmiX.
We’d like to remind you that:
Registration for Shivom’s Presale is completely secure – we are using the most secure platform for investing in our OmiX token, so you don’t have to worry about ICO scams. Make sure to complete your KYC on our platform in order to receive OmiX tokens in your wallet at the end of the sale.
For more details see our step by step guide:
https://medium.com/@
Don’t miss earning your bonuses as this will expire on the last day of the presale – April 22nd, 2018.
If you haven’t yet been able to register, complete your KYC or purchase tokens, do so now on our tokensale dashboard at https://tokensale.shivom.io/.
There are also additional discounts to be earned by sending your unique referral link from the platform to all your contacts.
About Shivom
Shivom combines blockchain, A.I., DNA sequencing & cryptography to enable secure and personalized medicine. The Shivom platform works on collaboration & integrity, allowing people to own, manage and monetize their data. By creating a web-marketplace, a network of genomic counsellors, and a not-for-profit drug research unit, Shivom will build a global healthcare ecosystem, reaching even low-income countries.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
